Eur Respir J. 2015 Mar 5. pii: ERJ-00973-2014. [Epub ahead of print]
Couraud S1,
Debieuvre D1,
Moreau L1,
Dumont P1,
Margery J1,
Quoix E1,
Duvert B1,
Cellerin L1,
Baize N1,
Taviot B1,
Coudurier M1,
Cadranel J1,
Missy P1,
Morin F1,
Mornex JF1,
Zalcman G1,
Souquet PJ1;
on behalf of the BioCAST/IFCT-1002 study investigators.
- 1For a list of the authors' affiliations see the Acknowledgements section.
Abstract
EGFR and HER2 mutations and ALK rearrangement are known to be related to lung cancer in never-smokers, while KRAS, BRAF and PIK3CA mutations are typically observed among smokers. There is still debate surrounding whether never-smokers exposed to passive smoke exhibit a "smoker-like" somatic profile compared with unexposed never-smokers. Passive smoke exposure was assessed in the French BioCAST/IFCT-1002 never-smoker lung cancer cohort and routine molecular profiles analyses were compiled. Of the 384 patients recruited into BioCAST, 319 were tested for at least one biomarker and provided data relating to passive smoking. Overall, 219 (66%) reported having been exposed to passive smoking. No significant difference was observed between mutation frequency and passive smoke exposure (EGFR mutation: 46% in never exposed versus 41% in ever exposed; KRAS: 7% versus 7%; ALK: 13% versus 11%; HER2: 4% versus 5%; BRAF: 6% versus 5%; PIK3CA: 4% versus 2%). We observed a nonsignificant trend for a negative association between EGFR mutation and cumulative duration of passive smoke exposure. No association was found for other biomarkers. There is no clear association between passive smoke exposure and somatic profile in lifelong, never-smoker lung cancer.
No comments:
Post a Comment